March 10, 2023
Eisai CEO Haruo Naito Eisai is expecting that global sales of its new Alzheimer’s drug Leqembi (lecanemab) will reach the “1 trillion-yen-level” in FY2030, CEO Haruo Naito said on March 9. At a media briefing held in Tokyo, the CEO...read more